AstraZeneca and Daiichi Sankyo have submitted a ... datopotamab deruxtecan as a monotherapy and in combination with other anticancer treatments in various settings. AstraZeneca and Daiichi Sankyo ...

AstraZeneca’s earnings were boosted by its oncology, cardiovascular, respiratory and immunology (R&I), and rare disease ...

Patients with actionable genomic alterations were previously treated with an approved targeted therapy and platinum ... as a monotherapy and in combination with other anticancer treatments in various ...

LONDON — AstraZeneca said Tuesday it has had to resubmit a closely watched medicine for U.S. approval in a different form of ...

AstraZeneca (AZN) and Daiichi Sankyo have submitted a new Biologics License Application ... including an EGFR-directed therapy. The companies have voluntarily withdrawn the BLA in the US for ...

The tenosynovial giant cell tumor (TGCT) trial hit its primary endpoint, teeing up an option decision that could establish ...

AstraZeneca and Daiichi Sankyo have submitted a new biologics license application (BLA) for accelerated approval for ...

AstraZeneca and Daiichi Sankyo have changed up their approval plans for a closely ... AstraZeneca and Daiichi have found ...

Aileen Lamb hopes the approval of a new cancer treatment drug will give patients 'hope', after she was given the all clear ...

Daiichi Sankyo & AstraZeneca’s Enhertu receives 2024 Prix Galien USA Award for Best Biotechnology Product: Tokyo Monday, November 11, 2024, 09:00 Hrs [IST] Daiichi Sankyo and As ...

Researchers in the field have a keen interest in combination strategies, such as CAR T-cell therapy plus immune checkpoint ...